Third Rock Ventures raises $1.1 billion Fund VI

15 June 2022
third-rock-ventures-large

Boston, USA-based Third Rock Ventures today announced the closing of Third Rock Ventures Fund VI, raising $1.1 billion.

Fund VI will continue Third Rock’s core strategy to discover, launch and build new ground-breaking companies focused on improving the lives of patients. Third Rock employs a hands-on approach to partnering with founders to build companies and provides early and rigorous integration of science, medicine, business and strategy to build successful companies.

“An important differentiator for Third Rock is the strength and maturity of our ideation ecosystem,” said Reid Huber, a partner at Third Rock, adding: “Our discovery pipeline is as robust as it has ever been, and with our established and proven model for integrating deep scientific and medical expertise with operational and business acumen, we are uniquely positioned to advance these innovations to patients.”

$3.8 billion raised to date

To date, Third Rock has raised $3.8 billion and its funds have invested in 60 companies. Importantly, companies across the portfolio have brought 18 products to the market across multiple therapeutic modalities and a broad range of disease indications including cancer, cardiovascular disease, depression, sickle cell disease, and rare genetic diseases among others. Fund VI is able to provide both initial Series A as well as follow-on capital to support companies throughout their lifecycle. Furthermore, Third Rock intends to allocate capital from Fund VI to invest in ground-breaking new companies from in the broader biotech ecosystem that are strongly aligned with Third Rock’s mission and strategy.

“We believe that people are our greatest asset, and we invest significant effort and resources to ensure we hire the best people at Third Rock and across the portfolio,” said Abbie Celniker, a partner at Third Rock, noting that “the internal team at Third Rock consists of ideators, experienced company builders, technology developers, and domain experts critical to the success of developing companies.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical